• Original article (Clinical research) • Previous Articles     Next Articles

Effects of sitagliptin combined with metformin for type 2 diabetes mellitus: a meta-analysis

CHU Jing-jing1, XU Zhe-rong2, DING Cheng1, SHEN Yi1   

  1. 1.Department of Epidemiology and Health Statistics, School of Public Health, Zhejiang University, Hangzhou 310058, China; 2.Department of Geriatrics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
  • Online:2013-11-28 Published:2013-12-03


Objective To assess the effects and safety of sitagliptin (SITA) combined with metformin (MET) in treating type 2 diabetes mellitus (T2DM). Methods The Cochrane Library, PubMed, EMbase, CNKI Database, WangFang Database, and VIP Database were searched to collect the randomized controlled trials (RCTs) on SITA combined with MET versus MET in treating T2DM. Meta-analysis was performed using RevMan 5.2 software in accordance with the Cochrane Collaboration. Results A total of 12 RCTs involving 3 200 patients were included. The results of metaanalysis showed that, compared to MET alone, SITA combined with MET effectively improved glycosylated hemoglobin levels [WMD=-0.69%,95%CI (-0.85, -0.53), P<0.000 01] and fasting plasma glucose levels [WMD=-0.91%,95%CI (-1.14,-0.69),P<0.000 01], and increased insulin sensitivity and β-cell function [WMD=-0.54,95%CI (-0.99,-0.10),P=0.02]. But there were no significant differences between the two groups in body mass index and the percentage of patients with adverse events (P>0.05). Conclusion Compared to using MET alone, SITA combined with MET can improve glycemic control, and there is no statistical difference of adverse events.

Key words: sitagliptin, metformin, type 2 diabetes mellitus, meta-analysis